Neil Minkoff, MD

A panel of experts discuss monitoring outcomes and effective patient-centered interventions to improve care for patients with cardiorenal metabolic syndrome.

Om P. Ganda, MD, discusses population health-management tactics to improve patient outcomes in cardiorenal metabolic syndrome.

Jeffrey Turner, MD, and Nihar R. Desai, MD, MPH, provide insight into the identification of high-risk patients with cardiorenal metabolic syndrome and the impact of case-management resources on patient outcomes.

Nihar R. Desai, MD, MPH, and Om P. Ganda, MD, discuss care pathways and the clinical utility of SGLT2 inhibitors and GLP-1 receptor agonists in heart failure.

Nihar R. Desai, MD, MPH; Neil Minkoff, MD; and Om P. Ganda, MD, discuss SGLT2 inhibitor utilization and managed care considerations in cardiorenal metabolic syndrome.

Om P. Ganda, MD, provides an overview of the clinical trials supporting the use of SGLT2 inhibitors and GLP-1 receptor agonists in cardiovascular and renal indications, and Jeffrey Turner, MD, comments on the kidney disease outcome measures of these trials.

Jeffrey Turner, MD, discusses the discovery of cardiovascular and renal benefits in SGLT2 inhibitors, and Nihar R. Desai, MD, MPH, provides insight into the role of SGLT2 inhibitors in the four pillars of heart failure.

Nihar R. Desai, MD, MPH, and Om P. Ganda, MD, provide an overview of the standard of care treatments and the collaboration across clinical guidelines to manage cardiorenal metabolic syndrome.

A panel of experts led by Neil Minkoff, MD, discuss health care resource utilization and economic burden associated with cardiorenal metabolic syndrome.

Jeffrey Turner, MD, and Nihar R. Desai, MD, MPH, discuss coordination of care between specialties, and Om P. Ganda, MD, provides insight into the goals of therapy and population health outcomes in cardiorenal metabolic syndrome.

A panel of experts provide an overview of the pathophysiology, patient population, and prevalence of cardiorenal metabolic syndrome.

Experts in HIV provide closing thoughts on the future of PrEP, including improvement of uptake and addressing access disparities.

Key opinion leaders in HIV describe factors to consider when evaluating which patients may benefit from long-acting injectable PrEP therapies.

A multidisciplinary panel of experts discuss pipeline medications for PrEP and effects of the USPSTF grading on emerging therapies.

Key opinion leaders in MS provide closing thoughts on the future of MS treatment including digital therapeutics, new generics, and pipeline drugs on the horizon.

Thomas Leist, MD and Darin Okuda, MD describe the current landscape of disease guidelines and algorithms in MS treatment.

Experts in HIV provide insight into the Grade A recommendation for HIV PrEP by the U.S. Preventive Services Task Force (USPSTF) and its impact on patients, clinicians, and payers.

Key opinion leaders in HIV discuss nonadherence to HIV PrEP and methods to address patient “walk away.”

Ian Frank, MD and Jeffrey Crowley, MPH provide insight into engaging clinicians for increased assessment of patients for PrEP.

Experts in HIV discuss methods to address the low rate of HIV PrEP uptake among at-risk individuals.

Experts in MS discuss the challenges related to treatment selection and management when MS disease progression occurs.

Thomas Leist, MD and Darin Okuda, MD discuss clinical trials supporting the use of high efficacy MS therapies: ocrelizumab, ofatumumab, and cladribine.

MS specialists Darin Okuda, MD and Thomas Leist, MD discuss the viability of a generic-first treatment approach in MS.

Key opinion leaders in MS describe the impact of generic medication availability on the management of MS and cost of MS treatment.

A multidisciplinary panel of experts discuss challenges to monitoring patient adherence and persistence to HIV PrEP.

Ian Frank, MD and Jeffrey Crowley, MPH address HIV PrEP adherence and persistence issues in the clinical practice setting.

Experts in HIV provide insight into payer coverage of HIV PrEP and patient barriers for receiving PrEP.

Carl Schmid, MBA and Ian Frank, MD discuss the process of initiating HIV PrEP beginning with a clinical patient evaluation.

Darin Okuda, MD discusses the risk of undertreating MS patients and the avoidance of undertreatment with newer high-efficacy therapies.

MS specialist Thomas Leist, MD provides insights into the challenges of evaluating and monitoring patients with MS.